literature

HIV mutation literature information.

Research on the treatment effects and drug resistances of long-term second-line antiretroviral therapy among HIV-infected patients from Henan Province in China.

PMID: 30442114 2018 BMC infectious diseases

Table: V90I

Detection of minority drug resistant mutations in Malawian HIV-1 subtype C-positive patients initiating and on first-line antiretroviral therapy.

PMID: 29977795 2018 African journal of laboratory medicine

Result: Other NNRTI mutations, such as V90I, K103N, V106A/M, E138A, V179E, Y181C, Y188C/L and G190E were also found in one or two samples.

Table: V90I

Seroconversion on preexposure prophylaxis: a case report with segmental hair analysis for timed adherence determination.

PMID: 29683856 2018 AIDS (London, England)

Introduction: The reverse transcriptase gene also harbored two polymorphisms (V90I and V179I), and there were no mutations in the protease-encoding gene.

HIV-1 drug-resistant mutations and related risk factors among HIV-1-positive individuals experiencing treatment failure in Hebei Province, China.

PMID: 28114955 2017 AIDS research and therapy

Table: V90I

Polymorphisms and Mutational Covariation Associated with Death in a Prospective Cohort of HIV/AIDS Patients Receiving Long-Term ART in China.

PMID: 28099515 2017 PloS one

Result: For example, M41L and D67N had 16 (D218E, E44A, G190S, G196E, H221Y, I142V, K101E, L210W, L228R, L74V, M184V, R211K, T215F, V108I, V118I, and V179I) and nine (E44A, H208Y, H221Y, K70R, L210W

Surveillance of HIV-1 pol transmitted drug resistance in acutely and recently infected antiretroviral drug-naive persons in rural western Kenya.

PMID: 28178281 2017 PloS one

Table: V90I

Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome.

PMID: 28212411 2017 PloS one

Result: This patient had pre-existing NNRTI (V90I) resistance, was noncompliant (overall adherence rate = 84%), and discontinued study drug 21 days later (HIV-1 RNA = 330 copies/mL).

The infection staging and profile of genotypic distribution and drug resistance mutation among the human immunodeficiency virus-1 infected blood donors from five Chinese blood centers, 2012-2014.

PMID: 28622345 2017 PloS one

Discussion: Perhaps a result that some polymorphic accessory mutations such as: A71V/T and L10I/V on PIs; V106I and V90I on NNRTIs, commonly observed in previous studies, were no longer classified as PI minor DRMs and NNRTI resistance mutations in the updated Stanford HIVdb Program Genotypic Resistance Interpretation Algorithm (HIVdb version 8.3).

Upward trends of acquired drug resistances in Ethiopian HIV-1C isolates: A decade longitudinal study.

PMID: 29049402 2017 PloS one

Result: At T1, the NNRTIs resistance associated mutations were detected at a lower frequency [K103N (n = 2), V106M, Y181S, Y188L, V90I, K101E and G190A (n = 1 each)].

Table: V90I

Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial.

PMID: 28382208 2017 SAGE open medicine

Result: Other etravirine RAMs that each emerged in <5 VFs were V90I, E138G, E138K, and E138Q.

Result: The most frequently observed baseline etravirine RAMs were G190A (18/151), V90I (15/151), A98G (10/151), and K101E (9/151) (Supplementary Figure 1).

Browser Board

Co-occurred Entities

Filtrator